Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Chromatics Color Sciences International. Inc; CCSI -- Ignore unavailable to you. Want to Upgrade?

To: Robin who wrote (2575)	6/9/1998 8:19:00 PM
From: STLMD	Read Replies (3) \| Respond to of 5736

Robin, I have watched from the sidelines this company with a good product but which I decided to shy away from because of my doubt of market size. This week's action frightens me and leaves me to conclude that we small investors are merely pawns in a larger game of finance. Unless we understand the movements of the major players we are frequently doomed. Pursuant to previous posts of mine when deciding not to invest, I announce that CCSI has a great product. The market is the problem. If you read the FDA 510K statement in which CCSI Colormate III was approved, one finds that in CCSI studt full 1037 of the over 1300 babies in the sequential study were labelled as "normal" thus not having any hyperbilirubinemia. This means that according to company data and the report submitted to the FDA that fully 78% of all infants in the FDA study were normal and thus not part of the study. Fast forward to the company's claims that there will be approximately 2 tests per 4 million children per year, this directly contradicts CCSI FDA data. Asensio can read and consult the experts. Its not the product, its the market that has been greatly exaggerated. By my calculations, and based on current reimbursement for bili tests in the insurance industry, 2 tests X 22% X 4 million X $7 reimbursed per test leaves $12.32 million in yearly revenues. Becton and Dickinson probably want this product but must know that the market penetration of the product is between my number and the company's inflated number(IMHO with some credentials behind this). Please read my previous posts on this for my opinions. I am not invested, but do know the medical market from a practicing physician point of view and from an insurance co. medical director. I am just trying to share some information as I did earlier to help those with questions. I must end with how I started. I am frightened beyond my years as to the manipulation of the market and the insignificance that we small shareholders hold if we do not pay extraordinary attention to the details. Reference:http://www.exchange2000.com/~wsapi/investor/s-2698/reply-260 Good Evening, Stephen